पेमेट्रेक्सेड के इंटरैक्शन

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (पेमेट्रेक्सेड लेबल, चेतावनियां और सावधानियां)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (पेमेट्रेक्सेड लेबल, चेतावनियां और सावधानियां)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (इंडोमेथासिन लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (ऑक्साप्रोज़िन लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (डाइक्लोफेनाक लेबल, दवाओं के इंटरैक्शन)

Avoid diclofenac sodium/misoprostol for a period of two days before, the day of, and two days following administration of pemetrexed. (डाइक्लोफेनाक और मिसोप्रोस्टोल लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (नेप्रोक्सेन लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (पाइरोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (पेमेट्रेक्सेड लेबल, चेतावनियां और सावधानियां)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (फेनोप्रोफेन लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (फ्लर्बिप्रोफेन लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (मेफेनामिक एसिड लेबल, दवाओं के इंटरैक्शन)

In patients with creatinine clearance below 45 mL/min, the concomitant administration of meloxicam with pemetrexed is not recommended. (मेलोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (सुमाट्रिप्टान और नेप्रोक्सेन लेबल, दवाओं के इंटरैक्शन)

Dihydrofolate Reductase (DHFR) Inhibitors : Avoid concomitant use (e.g., trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (सेपियाप्टेरिन लेबल, दवाओं के इंटरैक्शन)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (सेलेकॉक्सिब लेबल, दवाओं के इंटरैक्शन)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (पेमेट्रेक्सेड लेबल, चेतावनियां और सावधानियां)

Pemetrexed Clinical Impact : Concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality. (पाज़ोपैनिब लेबल, चेतावनियां और सावधानियां)

Initiate supplementation with oral folic acid and intramuscular vitamin B 12 to reduce the severity of hematologic and gastrointestinal toxicity of PEMFEXY. (पेमेट्रेक्सेड लेबल, चेतावनियां और सावधानियां)

Initiate supplementation with oral folic acid and intramuscular vitamin B 12 to reduce the severity of hematologic and gastrointestinal toxicity of PEMFEXY. (पेमेट्रेक्सेड लेबल, चेतावनियां और सावधानियां)

…(38% versus 23%), thrombocytopenia (9% versus 5%), febrile neutropenia (9% versus 0.6%), and neutropenic infection (6% versus 0) were higher in patients who received pemetrexed plus cisplatin without vitamin supplementation as compared to patients who were fully supplemented with folic acid and vitamin B 12 prior to and throughout pemetrexed plus cisplatin treatment. (पेमेट्रेक्सेड लेबल, चेतावनियां और सावधानियां)